Category: Investor Perspectives

On his reasons for investing in AseptiScope: “There are really three main reasons. The first is that there’s an urgent need for better methods for reducing the risks of hospital-acquired infections. The second reason is, I believe there is a tremendous market opportunity. And then the third is, the solution you guys have built—it’s elegantly simple.”

• On his reasons for investing in AseptiScope: “When I was introduced to this technology, I was confident it targeted a major void in terms of stethoscope hygiene, because that is one part which has been quite neglected. Frankly so, many of the societies in the country have mentioned that too, and there have been publications in major journals like the Mayo Clinic Proceedings. The most compelling part is that it is filling a void, or a need, that exists right now… I do strongly believe it is for patient safety and best outcomes for the patients.”
• On why touch-free, aseptic stethoscope diaphragm barriers are a superior method over simply cleaning with alcohol in a medical space: “Alcohol is great for many things, but it is not perfect for everything. It is not a barrier. There are a lot of factors when you use alcohol. How do you rub your hands? For how long do you rub your hands? How do you clean your stethoscope? Those are all very subjective things that people do differently, whereas a barrier is a barrier… it eliminates that human factor, and all you’ve got to do is put it on, then strip it off once you’ve used it.”

• On his reasons for investing in AseptiScope: “There’s several reasons we felt this would be a good investment. One was the company characters itself, and that was if we felt the founders had a lot of skin in the game—careers and personal investments. To that end, we felt it would be a very lean operation and our funds would be used very efficiently. The other thing I was impressed with initially was the company already had multiple products in mind as a follow-on to your flagship product. So we felt this was not just a one-trick pony company, and that it had a bright future. Finally, it is a huge unaddressed market with high potential profits. The product is 100% effective versus any other kind of strategy in sterilizing a stethoscope. One of the encouraging things was the recurring revenue stream provided by a razorblade model…”
• On the design of AseptiScope’s flagship product, The DiskCover System: “It’s very simple, meaning it’s more reliable since there’s fewer things to break. It’s cost-efficient. The installation is simple, requiring just 4 screws in the wall, no power supply or any other ancillary support, and the touch-free execution: completely sterile.”

On his reasons for reinvestment and why he has confidence in AseptiScope and its leadership: “You guys have really hit the ball out of the park with your clinical market development plan. Frankly, the depth to which you guys attack it and the breadth to which you attack all the various issues that will affect the ultimate market adoption of this technology… You guys have, really, done it better than I see many billion dollar companies do it, and that’s obviously as a small start-up today. So, that gives me a lot of confidence, and I feel very strong about the plans.”